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Abstract 
 
An inactivated virus vaccine was prepared from a pathogenic isolate of feline 
immunodeficiency virus containing a mutation that ablated an endocytic sorting signal in 
the envelope glycoprotein, increasing expression on virions.  Cats immunized with 
inactivated preparations of this modified virus exhibited strong ELISA titers to Env.  
Evidence of protection following challenge demonstrated the potential of this approach to 
lentiviral vaccination.   
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Although several animal model systems have been developed to test lentivirus vaccines 18 
and numerous immunogens have been evaluated, the mechanisms underlying protective 
immunity and the essential components of an effective vaccine remain unclear.   FIV 
infection of the domestic cat is a useful model since it represents an immunosuppressive 
lentivirus in its natural host 18,23.  Vaccine-induced protection against FIV infection has 
been achieved using several immunogens, but protection has been restricted mainly to 
viruses of low virulence 8, with both inactivated virus vaccines and molecularly derived 
vaccines having been ineffective at protecting cats against homologous challenge with a 
pathogenic isolate9,11.  Previous studies have indicated that Env is an important 
component of efficacious vaccines, to stimulate cytotoxic T cells (CTL) and neutralizing 
antibodies (VNA)5,10.  To attempt to improve immunogenicity, our strategy was to 
prepare a vaccine from a pathogenic clone of FIV-GL8 engineered to express high levels 
of Env by means of a mutation preventing Env endocytosis.  In this way we aimed to 
reproduce high levels of Env in a native conformation.   
 
First we confirmed that FIV Env was endocytosed from the cell surface, as had been 
demonstrated for SIV Env 20.  Immunofluorescence microscopy of FIV-infected CrFK 
cells incubated at 4oC with the anti-FIV Env monoclonal antibody vpg71.2 22 
demonstrated only low surface expression compared with control antibody recognising 
CD29 (4B4).  However, when cells were incubated with antibody at 37oC, a marked 
increase in fluorescence was noted in intracellular sites (Figure 1a).  These data indicated 
that at 37oC Env was transiently expressed on the cell surface and then internalized.  In 
contrast, no change in the level of fluorescence was seen on the cells incubated with the 
control antibody at 4 or 37oC.   
 
The observation that FIV Env was rapidly endocytozed from the surface of infected cells, 
similar to other lentivirus Envs 17, led us to identify the tyrosine-containing endocytosis 
motif GYTVI, located between positions 820 and 824 of the env gene of the GL8Mya 
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molecular clone 9, corresponding to the GYxxΦ motif conserved in all SIV and HIV Envs 
3,4(Figure 1b).  To test the effect of ablating this motif in FIV env, we constructed the 
mutant GL8YI based on the GL8Mya molecular clone by polymerase chain reaction (PCR)-
mediated mutagenesis, incorporating the mutation Y821I.  Stocks of GL8YI were prepared 
following transfection in 3T3 cells using Superfect transfection reagent (QIAgen) 
followed by recovery into Mya-1 cells 19.  Evaluation of Env surface expression by FACS 
on Mya-1 cells infected with either GL8YI or the wild type GL8 clone (GL8WT) revealed 
that although GL8YI and GL8WT produced similar levels of FIV p24 when measured by 
ELISA (data not shown), surface expression of Env was markedly greater in cells 
infected with GL8YI (49%) compared to GL8WT (2.6%).  Furthermore, we compared the 
Env content of GL8WT and GL8YI by adsorbing equal amounts of the two viruses onto 
Galanthus nivalis lectin (GN)-coated microwells and comparing the ability of the 
adsorbed virions to bind FIV immune sera, using the method described previously6.  
Although similar amounts of p24 were present by immunoblotting (data not shown), 
GL8YI bound considerably more antibody than GL8WT, indicating a higher Env content in 
the mutated virions (Figure 1c).  Subsequently, an inactivated virus vaccine was prepared 
from paraformaldehyde-treated culture fluids of GL8YI-infected Mya-1 cells as described 
previously 12.   
 
Eight 11-week-old kittens were randomly divided into 2 groups of 4.  One group of 
kittens  (V1 to V4) was immunized subcutaneously at 0, 3 and 7 weeks with 250 µg 
inactivated GL8YI virus in 0.5 ml PBS and 0.5 ml MF 59.0 citrate adjuvant.  The controls 
(C1 to C4) received 0.5 ml PBS and 0.5 ml MF 59.0 citrate adjuvant at the same times.  
At week 10, three weeks following the third inoculation, no virus could be isolated from 
peripheral blood mononuclear cells (PBMC), confirming that the inactivated virus 
vaccine did not contain any residual infectivity for cats.   
 
FIV gp140 Env, consisting of the entire surface unit and the ectodomain of the 
transmembrane domain, was used as antigen in an ELISA to measure anti-Env antibodies 
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in cat sera.  The env gene of the FIV-GL8 molecular clone GL8414 9 was cloned by PCR 
into pPPI4 2 using KasI and BstB1, with the 3’ primer containing a C-terminal D7324 
epitope tag 1. An antigen-capture ELISA was developed, based on one described 
previously 1 in which supernatant containing FIV Env (approximately 1 µg/ml) derived 
from 293T cell transfections was captured using sheep antibody raised against the D7324 
epitope tag (Cliniqa, CA). Bound antibody was detected using goat anti-cat IgG Fc 
alkaline phosphatase conjugate (Accurate Chemical and Scientific, Westbury, NY) at 
1:5000 and the signal was amplified and developed as described previously1.  GL8YI 
vaccinates developed anti-Env antibodies, detectable by ELISA in all vaccinates (Table 
1), with the highest titer in vaccinate V4.   
 
To test whether the anti-Env antibodies were neutralizing, VNA were measured against 
10 50% tissue culture infectious doses (TCID50) of the GL8 molecular clone using MBM 
cells as previously described6, with or without prior adsorption of test sera with MBM or 
Mya-1 cells.  Vaccinates V1, V2 and V4 developed VNA against the GL8 challenge 
virus, provided that the sera were absorbed with either MBM or Mya-1 cells prior to 
testing.  It has been reported that the presence of antibodies to substrate cells can mask 
detection of VNA in vaccinated cats sera6 and in this study absorption of sera with Mya-1 
cells eliminated this in 2/4 sera whereas absorption of sera with the substrate MBM cells 
revealed neutralizing antibodies in 3/4 sera (Table 1). 
 
To assess whether immunization with GL8YI would protect against virulent challenge, all 
eight cats were challenged intraperitoneally with 10 50% infectious doses (ID50) of virus 
derived from the GL8 molecular clone at week 10.  The challenge virus was prepared 
from the GL8414 9 molecular clone of FIV by transfection of the murine fibroblast cell 
line 3T3 using Superfect transfection reagent (QIAgen, Valencia,CA.). 72 hours post 
transfection, supernatants were harvested, 0.45µm filtered and used to infect the IL2-
dependent feline T cell line Q201 21.  The infected cultures were monitored visually for 
cytopathicity and for the production of FIV p24 by enzyme-linked immunosorbent assay 
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(ELISA, PetCheck FIV antigen ELISA, IDEXX Corp., Portland, Maine, USA). 
Supernatants were collected at peak cytopathicity/ p24 production, 0.45µm filtered, 
dispensed into 1ml aliquots and stored at –70oC.  Previously we had demonstrated that 
infection of cats with a similar dose of this challenge stock led to a high proviral burden 
that was maintained throughout the acute phase of infection.  Coincident with the sharp 
rise in proviral load was a marked decline in the CD4:CD8 ratio 13, consistent with the 
pathogenic potential of the GL8 molecular clone challenge stock. 
 
Cultures of PBMC isolated from samples from all cats taken 3 weeks post challenge were 
positive by FIV p24 antigen ELISA after 7 days in culture, indicating that all of the 
vaccinated and control cats became infected following challenge.  However, we noted 
that a smaller proportion of PBMC was infected in three vaccinates compared to the 
remaining vaccinate (cat V3) and the control cats (data not shown) and so, to provide 
more quantitative information on the viral burdens following challenge, we examined 
proviral loads in PBMC at intervals until 21 weeks post challenge by real-time PCR7 
using oligonucleotides designed to detect a variety of FIV A-subtype isolates as 
described14-16 (Figure 2a).  The mean proviral load was consistently lower in the 
vaccinates than the controls, although the difference did not reach statistical significance 
because of the high proviral load of vaccinate V3 (Figure 2b).  Furthermore, the peak 
proviral loads in PBMC of 3/4 vaccinates were markedly lower than those of the controls 
(Figure 2c).  Supporting evidence that the virulent challenge was controlled in 3/4 
vaccinates was provided by the analysis of tissues sampled post mortem, 21 weeks after 
challenge (data not shown).  The highest proviral burden in splenocytes was in vaccinate 
V3, consistent with the high proviral load in the PBMC of this cat throughout the study.  
In contrast, the proviral loads of the remaining vaccinates were lower compared to the 
controls in both splenocytes and PBMC, although again these differences were not 
statistically significant.  Proviral DNA was detected in cells isolated from the mesenteric 
lymph node (MLN) from all of the control cats but only a single vaccinate (cat V3).  The 
high proviral loads detected in cat V3 were inconsistent with the remaining three 
vaccinates, providing no evidence of even partial protection against the challenge; indeed 
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the viral and proviral loads measured in this cat usually exceeded the loads in the 
unvaccinated, control cats, suggesting that the infection may have been enhanced.  Taken 
together, these data indicate that a larger vaccine trial is merited to test the applicability 
of this approach to lentiviral vaccines in general.   
 
 The mutated virus preparation did express increased levels of Env and immunization 
induced anti-Env responses in 4/4 cats and VNA in 3/4 cats.  The pilot challenge study 
led to encouraging results and, although vaccination did not prevent infection with the 
pathogenic GL8 molecular clone, the course of infection was modified in the cats that 
developed VNA, with decreased viral burdens compared to the controls.  Vaccinate V3, 
which developed very high viral and proviral loads following challenge, did not develop 
VNA.  It is tempting to speculate, therefore, that the VNA detected in the remaining three 
vaccinates played a role in reducing the viral burden. Thus the data indicate that Env is an 
important constituent of an effective lentiviral vaccine and encourage further studies to 
optimize immune responses against virulent isolates, since the GL8 molecular clone is 
pathogenic and achieves high virus loads similar to those described for other pathogenic 
strains (our unpublished observations).  It is possible that the quality of the humoral 
immune response generated against Env was sub optimal, since the vaccine appeared to 
induce VNA inefficiently.  Therefore, future studies might address methods of improving 
the quality of the VNA responses since the generation of protective immune responses in 
the domestic cat against challenge with the GL8 isolate would provide encouragement for 
the testing of similar strategies to increase the quantity of Env on HIV-1 or HIV-2 
virions. 
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Figure Legends 
 
Figure 1.  (a) Immunofluorescence of FIV-infected CrFK cells incubated with antibodies 
detecting either FIV Env or CD29 for 1 h at either 4oC or 37oC. (b) Conservation of 
endocytosis motif between feline and primate lentiviruses. (c) Relative Env content in the 
GL8WT (■) and GL8YI (□) clones was determined by measuring the ability of virions to 
bind anti-FIV antibody.  Equal amounts of gradient-purified virions of the two clones 
were adsorbed onto GN-coated microwells and then probed for the ability to bind IgG 
from cat sera diluted 1:100.  Cat sera from a GL8-infected cat, a PET-infected cat, and a 
serum pool from 5 uninfected control cats were used. The experiment was repeated twice 
with comparable results.   
 
Figure 2. Proviral loads in vaccinated (open symbols) and control (closed symbols) cats 
measured at intervals post challenge by real-time PCR.  The proviral loads of the 
individual cats (V3 represented by ∆) are shown in (a), the mean loads +/- SEM of the 
vaccinates (Ο) and the controls (•) are shown in (b) and the peak proviral loads in PBMC 
from vaccinated (□) and control (■) cats are shown in (c).  
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Table 1. Anti Env antibody responses and neutralizing activity of day of challenge 
vaccine and control sera.   
 
 Anti-Env titer VNA titer1 
Serum Determined by Cells used for sera adsorption 
 ELISA None MBM Mya-1 
Vaccinated     
V1 14 000 <8 128 128 
V2 5 000 <8 16 64 
V3 10 000 <8 <8 <8 
V4 80 000 <8 16 <8 
Control     
C1 <1 000 <8 <8 <8 
C2 <1 000 <8 <8 <8 
C3 <1 000 <8 <8 <8 
C4 <1 000 <8 <8 <8 
 
1 VNA titers were measured on untreated sera as well as cell-adsorbed sera as indicated 
and are expressed as the reciprocal of the highest serum dilution that gave 50% inhibition 
of reverse transcriptase production by 10 50% TCID50 GL8 clone mixed with the 
corresponding dilution of a pool of 10 normal cat sera.  The experiment was repeated 
twice, with comparable results.  
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